2. Search Result
Search Result
Results for "

FYN kinase

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

3

Peptides

2

Natural
Products

2

Recombinant Proteins

5

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13805
    PP2
    Maximum Cited Publications
    62 Publications Verification

    AGL 1879

    		 Src Cancer
    PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.
    PP2
  • HY-10234
    Saracatinib
    35+ Cited Publications

    AZD0530

    		 Src Autophagy Cancer
    Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases .
    Saracatinib
  • HY-13804
    PP1
    10+ Cited Publications

    AGL 1872; EI 275

    		 Src Apoptosis Cancer
    PP1 is a potent, and Src family-selective tyrosine kinase inhibitor with IC50 of 5 and 6 nM for Lck and Fyn, respectively.
    PP1
  • HY-B0789
    SU6656
    20+ Cited Publications

    		 Src FAK Akt Cancer
    SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.
    SU6656
  • HY-12624
    Narazaciclib
    2 Publications Verification

    ON123300

    		 CDK AMPK PDGFR Cancer
    Narazaciclib (ON123300), a strong and brain-penetrant multi-kinase inhibitor, inhibits CDK4 (IC50=3.9 nM), Ark5 (IC50=5 nM), PDGFRβ (IC50=26 nM), FGFR1 (IC50=26 nM), RET (IC50=9.2 nM), and FYN (IC50=11 nM). Single agent Narazaciclib causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors . Narazaciclib inhibits CDK6 with an IC50 of 9.82 nM .
    Narazaciclib
  • HY-13942
    1-NM-PP1
    5+ Cited Publications

    PP1 Analog II

    		 Src Cancer
    1-NM-PP1, a cell-permeable PP1 analog, is a potent Src family kinases inhibitor with IC50s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively .
    1-NM-PP1
  • HY-13941
    1-Naphthyl PP1
    3 Publications Verification

    1-NA-PP 1

    		 Src PKD Neurological Disease Inflammation/Immunology Cancer
    1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of src family kinases and Protein Kinase D. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively .
    1-Naphthyl PP1
  • HY-11011
    A-770041
    5+ Cited Publications

    		 Src Inflammation/Immunology
    A-770041 is a selective and orally active Src-family Lck inhibitor. A-770041 inhibits Lck with an IC50 value of 147 nM with the presence of 1 mM ATP. A-770041 shows 300-fold selective to Lck over Fyn, the other Src family kinase involved in T-cell signaling. A-770041 can be used for the research of acute rejection .
    A-770041
  • HY-N4099
    Luteolin-3-O-beta-D-glucuronide

    		Drug Metabolite Inflammation/Immunology
    Luteolin-3-O-beta-D-glucuronide, a glucuronide derivative of Luteolin (HY-N0162), is found in the leaves of Rosmarinus officinalis L. Luteolin-3-O-beta-D-glucuronide inhibits nitrite production in macrophages and binds strongly to FYN kinase .
    Luteolin-3-O-beta-D-glucuronide
  • HY-13941B
    1-Naphthyl PP1 hydrochloride
    3 Publications Verification

    1-NA-PP 1 hydrochloride

    		 Src PKD Neurological Disease Inflammation/Immunology Cancer
    1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases and Protein Kinase D. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively .
    1-Naphthyl PP1 hydrochloride
  • HY-14340
    WAY-181187
    2 Publications Verification

    SAX-187

    		 5-HT Receptor Neurological Disease
    WAY-181187 (SAX-187) is a potent and selective full 5-HT6 receptor agonist with a Ki of 2.2 nM and an EC50 of 6.6 nM . WAY181187 mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist .
    WAY-181187
  • HY-10185
    TG 100572 Hydrochloride
    3 Publications Verification

    		 Src VEGFR FGFR PDGFR Inflammation/Immunology
    TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100572 Hydrochloride
  • HY-144290
    ARN25068

    		GSK-3 DYRK Neurological Disease
    ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .
    ARN25068
  • HY-10186
    TG 100801
    1 Publications Verification

    		 VEGFR FGFR PDGFR Src Cancer
    TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100801
  • HY-176892
    Papaveroline

    		Src Neurological Disease
    Papaveroline is an orally active Fyn tyrosine kinase inhibitor. Papaveroline stably binds to the active site of Fyn tyrosine kinase via hydrogen bonding and hydrophobic interactions, thereby inhibiting kinase activity associated with the pathogenesis of Alzheimer's disease. Papaveroline can be used for the research of Alzheimer's disease .
    Papaveroline
  • HY-10234A
    Saracatinib difumarate
    35+ Cited Publications

    AZD0530 difumarate

    		 Src Cancer
    Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .
    Saracatinib difumarate
  • HY-10184
    TG 100572

    		Src VEGFR PDGFR FGFR Cancer
    TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100572
  • HY-155587
    Hydroxy-PP

    		Carbonyl Reductase Src Cancer
    Hydroxy-PP is a potent carbonyl reductase 1 (CBR1) inhibitor with an IC50 value of 0.78 μM. Hydroxy-PP also potently inhibits the cytoplasmic tyrosine kinase Fyn with an IC50 value of 5 nM .
    Hydroxy-PP
  • HY-10187
    TG 100801 Hydrochloride

    		VEGFR FGFR PDGFR Src Cancer
    TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100801 Hydrochloride
  • HY-W746031
    WAY-181187 hydrochloride

    SAX-187 hydrochloride

    		 5-HT Receptor Neurological Disease
    WAY-181187 (SAX-187) hydrochloride is a potent and selective full 5-HT6 receptor agonist with a Ki of 2.2 nM and an EC50 of 6.6 nM . WAY-181187 hydrochloride mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist .
    WAY-181187 hydrochloride
  • HY-E70726
    FYN Y531F Recombinant Human Active Protein Kinase

    		Src Cancer
    FYN Y531F Recombinant Human Active Protein Kinase is an oncogene that directly activated YANK2 through phosphorylation its Y110, and Fyn-mediated YANK2 phosphorylation at Y110 site promotes glioma growth by increasing its stability .
    FYN Y531F Recombinant Human Active Protein Kinase
  • HY-E70725
    FRK Recombinant Human Active Protein Kinase

    		Src Cancer
    FRK Recombinant Human Active Protein Kinase, a non-receptor tyrosine kinase Fyn-related kinase, is a member of the BRK family kinases (BFKs). FRK may be involved in tumor progression .
    FRK Recombinant Human Active Protein Kinase
  • HY-P10372
    pFYN peptide

    		Src Cancer
    pFYN peptide is a biotin-labled phosphorylated peptide substrate derived from FYN (a Src family kinase) .
    pFYN peptide
  • HY-13805R
    PP2 (Standard)

    AGL 1879 (Standard)

    		 Src Reference Standards Cancer
    PP2 (Standard) is the analytical standard of PP2. This product is intended for research and analytical applications. PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC50s of 4 and 5 nM for Lck and Fyn, respectively.
    PP2 (Standard)
  • HY-10234AR
    Saracatinib difumarate (Standard)

    AZD0530 difumarate (Standard)

    		 Src Reference Standards Cancer
    Saracatinib (difumarate) (Standard) is the analytical standard of Saracatinib (difumarate). This product is intended for research and analytical applications. Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .
    Saracatinib difumarate (Standard)
  • HY-10234R
    Saracatinib (Standard)

    AZD0530 (Standard)

    		 Reference Standards Src Autophagy Cancer
    Saracatinib (Standard) is the analytical standard of Saracatinib. This product is intended for research and analytical applications. Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases .
    Saracatinib (Standard)
  • HY-110366
    WAY-181187 oxalate

    SAX-187 oxalate

    		 5-HT Receptor Neurological Disease
    WAY-181187 (SAX-187) oxalate is a potent and selective full 5-HT6 receptor agonist with a Ki of 2.2 nM and an EC50 of 6.6 nM. WAY-181187 oxalate mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist .
    WAY-181187 oxalate
  • HY-176892A
    Papaveroline hydrochloride

    		Src Neurological Disease
    Papaveroline hydrochloride is an orally active Fyn tyrosine kinase inhibitor. Papaveroline hydrochloride stably binds to the active site of Fyn tyrosine kinase via hydrogen bonding and hydrophobic interactions, thereby inhibiting kinase activity associated with the pathogenesis of Alzheimer's disease. Papaveroline hydrochloride can be used for the research of Alzheimer's disease .
    Papaveroline hydrochloride
  • HY-N4099R
    Luteolin-3-O-beta-D-glucuronide (Standard)

    		Reference Standards Drug Metabolite Inflammation/Immunology
    Luteolin-3-O-beta-D-glucuronide (Standard) is the analytical standard of Luteolin-3-O-beta-D-glucuronide (HY-N4099). This product is intended for research and analytical applications. Luteolin-3-O-beta-D-glucuronide, a glucuronide derivative of Luteolin (HY-N0162), is found in the leaves of Rosmarinus officinalis L. Luteolin-3-O-beta-D-glucuronide inhibits nitrite production in macrophages and binds strongly to FYN kinase .
    Luteolin-3-O-beta-D-glucuronide (Standard)
  • HY-10185R
    TG 100572 hydrochloride (Standard)

    		Reference Standards Src VEGFR FGFR PDGFR Inflammation/Immunology
    TG 100572 hydrochloride (Standard) is the analytical standard of TG 100572 hydrochloride (HY-10185). This product is intended for research and analytical applications. TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100572 hydrochloride (Standard)
  • HY-183584
    ARN25699

    		GSK-3 Src DYRK Tau Protein Microtubule/Tubulin Neurological Disease
    ARN25699 is a kinase inhibitor with an IC50 of 5.5 nM against GSK-3β, 2.2 nM against FYN-α, and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and related tauopathies .
    ARN25699

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: